期刊
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY
卷 14, 期 2, 页码 -出版社
ELSEVIER - DIVISION REED ELSEVIER INDIA PVT LTD
DOI: 10.1016/j.jceh.2023.09.008
关键词
-
Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. Prevention of recurrence in hepatitis B cases is crucial. The introduction of direct-acting antivirals has made the treatment of hepatitis C considerably easier. In patients with advanced HCV-related cirrhosis, transplantation is recommended first, followed by treatment after liver transplantation. Sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era.
Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplantation. After the introduction of direct-acting antivirals, the treatment of HCV has become considerably easy. In patients with advanced HCV-related cirrhosis, it is better to do transplantation first and treat them after liver transplantation. The sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era. In the current review, we discuss the treatment of HBV and HCV before and after liver transplantation. ( J CLIN EXP HEPATOL 2024;14:101287)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据